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RESUMEN
Se ha sintetizado una nueva serie de pirimidopirimidinas 
partiendo de 6-amino-1-benzyl [o 1-(2-chlorobenzyl)] ura-
cilo a través de la formación de un aducto de Michael no 
aislado seguido de adición nucleofílica y aromatización fi-
nal. El mismo material de partida puede ser utilizado para 
la preparación de algunas nuevas pirimidodipirimidinas 
por reflujo con diferentes aldehídos en medio ligeramente 
básico. Finalmente se han sintetizado diferentes lumazinas 
vía reacción de tipo SN
2 entre clorhidrato de diaminouracilo 
con bromuro de fenacilo seguida de ciclodeshidratación 
intramolecular y aromatización. Estos nuevos compuestos 
de síntesis mostraron propiedades de combinación, que-
lación y fragmentación del ácido nucleico ADN. 
Palabras clave: 6-Amino-1-bencil [o 1-(2-clorobenzil)] 
uracilo, clorhidrato de diaminouracilo, pirimidopirimidinas, 
pirimidodipirimidinas y lumazinas.
SUMMARY
A new series of pyrimidopyrimidines are synthesized start-
ing from 6-amino-1-benzyl[or1-(2-chlorobenzyl)]uracil via 
the formation of nonisolable acyclic Michael type adduct 
followed by nucleophilic addition and finally aromatization. 
The same starting material can be used for the preparation 
of some new pyrimidodipyrimidines by refluxing with dif-
ferent aldehydes in slightly basic medium. Finally different 
lumazines are synthesized via SN2 type reaction of diami-
nouracil hydrochloride with phenacyl bromides followed 
by intramolecular cyclodehydration then aromatization. 
The newly synthesized compounds showed binding, che-
lation and fragmentation of the nucleic acid DNA.
Keywords: 6-Amino-1-benzyl[or1-(2-chlorobenzyl)]uracil, 
diaminouracil hydrochloride, pyrimidopyrimidines, pyrimi-
dodipyrimidines and lumazines.
RESUM
S’ha sintetitzat una nova sèrie de pirimidopirimidines 
partint de 6-amino-1-benzyl [o 1-(2-chlorobenzyl)] uracil 
a través de la formació d’un aducte de Michael no aïllat 
seguit d’addició nucleofílica i aromatització final. El ma-
teix material de partida pot ser utilitzat per a la prepara-
ció d’algunes noves pirimidodipirimidines per reflux amb 
diferents aldehids en medi lleugerament bàsic. Finalment 
s’han sintetitzat diferents lumazines via reacció de tipus 
SN2 entre clorhidrat de diaminouracil amb bromur de fe-
nacil seguida de ciclodeshidratació intramolecular i aro-
matització. Aquests nous compostos de síntesis van mos-
trar propietats de combinació, quelació i fragmentació de 
l’àcid nucleic ADN.
Paraules clau: 6-Amino-1-bencil [o 1-(2-clorobenzil)] ura-
cil, clorhidrato de diaminouracil, pirimidopirimidines, piri-
midodipirimidines i lumazines.
INTRODUCTION
Resistance of tumor cells to chemotherapeutic agents is 
a major problem in the treatment of human malignancy.1-3 
The causes of drug resistance fall into two groups; firstly, 
those leading to inadequate drug exposure and, secondly, 
alterations in the cancer cell itself that affect drug sensitiv-
ity.4 Differences in the metabolic and structural properties 
of cells may lead to drug-resistant phenotypes.5 The anti-
metabolite group of drugs blocks the de novo synthesis of 
the purines and pyrimidines required for DNA synthesis.5-7 
Resistance has been reported due to the increased ac-
tivities of the enzymes in alternative pathways for purine 
and pyrimidine biosynthesis, the salvage pathways.5,7,8 
The inhibitory activity of an antimetabolite depends on its 
successful competition with the corresponding metabolite 
for the enzymes of which the metabolite is the natural sub-
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strate or cofactor. A series of nonnucleoside drugs as fla-
vin analogues9-11 e.g. alloxazine9 have exhibited antitumor 
activity against different tumor cell lines. 5-Fluorouracil12,13, 
methotrexate (MTX)14,15 is the oldest antifolate anticancer 
drugs,16 which is widely used as chemotherapeutic drug. 
It competes with the normal substrates, folic acid and di-
hydrofolate, for the active site on the enzyme dihydrofolate 
reductase (DHFR).2,17,18 Mild reduction in reduced folates 
at low serum concentrations of MTX results in inhibition of 
pyrimidine (i.e. thymidine) synthesis.19,20 Thus, by inhibit-
ing DHFR, methotrexate prevents DNA synthesis and kills 
cells by depleting thymidylic acid.21-23  We rationalized to 
synthesize new series of bicyclic fused uracil of pyridopy-




All melting points were determined with an Electrothermal 
Mel.-Temp. II apparatus and were uncorrected.  Element 
analyses were performed at the Micro Analytical Unit, 
Chemistry Department, Mansoura University.  The infra-
red (IR) spectra were recorded using potassium bromide 
disc technique on Nikolet IR 200 FT IR at Pharmaceutical 
Analytical Unit, Faculty of Pharmacy, Al-Azhar University. 
The proton nuclear magnetic resonance (1H-NMR) spectra 
were recorded on Varian Gemini 300 MHz Spectrometer 
using DMSO-d6 as a solvent and tetramethylsilane (TMS) 
as an internal standard (Chemical shift in δ, ppm), Faculty 
of Science, Chemistry Department, Cairo University.  Mass 
spectra were recorded on DI-50 unit of Shimadzu GC/
MS-QP 5050A at the Regional Center for Mycology and 
Biotechnology at Al-Azhar University.  All reactions were 
monitored by TLC using precoted plastic sheets silica gel 
(Merck 60 F254) and spots were visualized by irradiation 
with UV light (254 nm). The used solvent system was chlo-
roform: methanol (9:1) & ethyl acetate:toluene (1:1).
7-Amino-5-aryl-1-(2-chlorobenzyl)-6-cyanopyrido[2,3-
d]pyrimidine-2,4(1H,3H)-diones (2a-d)
Two methods were used to synthesize the target com-
pounds:
A-  A mixture of 6-amino-1-(2-chlorobenzyl)uracil (1b) 
(0.3 g, 1.2 mmol) and the appropriate benzylidene-
malononitrile (1.2 mmol) in DMF (3 ml) in the presence 
of TEA (0.3 ml) was heated under reflux for 6-8 hours. 
The reaction mixture was evaporated under reduced 
pressure.  The residue was treated with ethanol (10 
ml), the formed precipitate was filtered, washed with 
ethanol and crystallized from DMF/ethanol (2:1) to af-
ford 2a-d.
B-  A mixture of 6-amino-1-(2-chlorobenzyl)uracil (1b) 
(0.3 g, 1.2 mmol) and the appropriate benzylidene-
malononitrile (1.2 mmol) in sodium ethoxide (0.3 g Na 
in 15 ml absolute ethanol) was heated under reflux for 
10 hours.  Hydrochloric acid was added till pH=7, the 
formed precipitate was filtered, washed with ethanol 
and crystallized from DMF/ethanol (2:1) to afford 2a.
7-Amino-1-(2-chlorobenzyl)-5-(4-chlorophenyl)-6-
cyanopyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (2a) 
Yield: A 82%, B 86%, m.p.= >330ºC. IR= 3335, 3191(NH2& 
NH), 3069 (CH arom.), 2918, 2849 (CH aliph.), 2222 (CN), 
1710, 1667 (2 C = O), 1627 (C = N), 1559 (C = C), 820 (p-
substituted phenyl), 755 (o-substituted phenyl). 1H-NMR 
(DMSO-d6) δ 11.34 (bs, 1H, NH), 7.70 (bs, 2H, NH2), 7.51-
7.48 (m, 2H, arom.), 7.34-7.25 (m, 4H, arom.), 7.06-7.04 
(m, 2H, arom.), 5.35 (s, 2H, NCH2). MS: m/z 439 (M++2, 
0.9), 437 (M+, 1.73), 404 (38), 402 (100). Anal. Calcd for 
C21H13Cl2N5O2 (438.26), Calcd.: C, 57.55, H, 2.99, N, 15.98, 
Found: C, 57.25, H, 3.45, N, 15.79.
7-Amino-1-(2-chlorobenzyl)-5-(4-fluorophenyl)-6-
cyanopyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (2b) 
Yield: A 81%, m.p.= 312-314° C. IR= 3311, 3226 (NH2& 
NH), 3072 (CH arom.), 2923, 2844 (CH aliph), 2219 (CN), 
1701, 1665 (2 C = O), 1637 (C = N), 1560 (C = C), 803 
(p-substituted phenyl), 754 (o-substituted phenyl). Anal. 
Calcd for C21H13ClFN5O2 (421.81), Calcd.: C, 59.80, H, 
3.11, N, 16.60, Found: C, 59.37, H, 3.10, N, 16.51. 
7-Amino-1-(2-chlorobenzyl)-5-(2-methoxyphenyl)-6-
cyanopyrido[2,3-d]pyrimidine-2,4(1H, 3H)-dione (2c)
Yield: A 89%, m.p.= 316-318° C. IR= 3310, 3227 (NH2& 
NH), 3074 (CH arom.), 2953, 2838 (CH aliph), 2217 (CN), 
1702, 1665 (2 C = O), 1635 (C = N), 1557 (C = C), 755 
(o-substituted phenyl). 1H-NMR (DMSO-d6) δ 11.32 (s, 1H, 
NH, exchangeable), 7.70 (bs, 2H, NH2, exchangeable), 
7.51-7.48 (m, 2H, arom.), 7.48-7.40 (m, 2H, arom.), 7.40-
6.98 (m, 4H, arom.), 5.43-5.29 (two d, 2H, NCH2), 3.72 (s, 
3H, OCH3). Anal. Calcd for C22H16ClN5O3 (433.84), Calcd.: 




Yield: A 63%, m.p.= 293-295° C. IR= 3441 (OH), 3336, 
3227 (NH2& NH), 3070 (CH arom.), 2980 (CH aliph), 2224 
(CN), 1690-1641 (br, C = O), 1569 (C = C &/or C = N), 821 
(p-substituted phenyl), 754 (o-substituted phenyl). Anal. 
Calcd for C21H14ClN5O3 (419.82), Calcd.: C, 60.08, H, 3.36, 
N, 16.68, Found: C, 60.15, H, 3.81, N, 17.00.
5-Aryl-1-benzyl[or 1-(2-chlorobenzyl)]pyrido[2,3-d] py-
rimidine-2,4,7(1H,3H,8H)-triones (3a-d)
A mixture of the appropriate 6-amino-1-benzyluracil 1a or 
b (1.2 mmol) and ethyl arylidenacetoacetate (1.2 mmol) in 
DMF (3 ml) in the presence of TEA (0.3 ml) was heated un-
der reflux for 6-8 hours.  The reaction mixture was evapo-
rated under diminished pressure.  The residue was treated 
with ethanol (10 ml), the formed precipitate was filtered, 
washed with ethanol and crystallized from DMF/ethanol 
(3:1) to afford the target pyridopyrimidines 3a-d.
1-Benzyl-5-(4-chlorophenyl)pyrido[2,3-d]pyrimidine-
2,4,7(1H,3H,8H)-trione (3a)
Yield: 58%, m.p.= 250-252 °C. IR= 3160 (NH), 3028 (CH 
arom.), 2920, 2848 (CH aliph.), 1693 (C = O), 1596 (C = C), 
829 (p-substituted phenyl). 1H-NMR (DMSO-d6)  δ 11.79 
(bs, 1H, NH), 8.40-8.37 (d, 1H, arom.), 8.11-8.08 (d, 2H, 
arom.), 7.87-7.85 (d, 1H, arom.), 7.56-7.53 (d, 2H, arom.), 
7.38- 7.22 (m, 4H, arom.), 7.20 (bs, 1H, NH &/or OH), 5.45 
(s, 2H, NCH2). MS: m/z 379 (M
+, 0.62), 91 (100). Anal. 
Calcd for C20H14ClN3O3 (379.79), Calcd.: C, 63.25, H, 3.72, 
N, 11.06,  Found: C, 63.00, H, 3.68, N, 10.88.
1-(2-chlorobenzyl)-5-(4-nitrophenyl)pyrido[2,3-d]py-
rimidine-2,4,7(1H,3H,8H)-trione (3b)
 Yield: 62%, m.p.= 318-320 °C. IR= 3224 (NH), 3073 (CH 
arom.), 2964, 2846 (CH aliph), 1710 (C = O), 1564 (C = 
C), 1519, 1347 (NO2), 826 (p-substituted phenyl), 751 (o-
substituted phenyl). Anal. Calcd for C20H13ClN4O5 (424.79), 
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Yield: 67%, m.p.= 268-270 °C. IR= 3238 (NH), 3089 (CH 
arom.), 2829 (CH aliph), 1700, 1631 (C = O), 1500 (C = 
C), 820 (p-substituted phenyl), 753 (o-substituted phenyl). 
Anal. Calcd for C20H13BrClN3O3 (458.69), Calcd.: C, 52.37, 
H, 2.86, N, 9.16, Found: C, 52.30, H, 2.88, N, 8.85.
1-(2-chlorobenzyl)-5-(4-hydroxyphenyl)pyrido[2,3-d]
pyrimidine-2,4,7(1H,3H,8H)-trione (3d)
 Yield: 51%, m.p.= > 330 °C. IR= 3416 (OH), 3254 (NH), 
3087 (CH arom.), 2838 (CH aliph.), 1694, 1621 (C = O), 
1506 (C = C), 830 (p-substituted phenyl), 756 (o-substitut-
ed phenyl). Anal. Calcd for C20H14ClN3O4 (395.79), Calcd.: 
C, 60.69, H, 3.57, N, 10.62, Found: C, 60.52, H, 3.44, N, 
10.34.
5,5’-Methylene bis(6-amino-1-benzyluracil) (4)
A mixture of 6-amino-1-benzyluracil (1a) (0.3 g, 1.4 mmol) 
and excess formalin (2 ml) in ethanol (20 ml) in the pres-
ence of acetic acid (3 ml) was stirred at room temperature 
for 1 hour.  The formed precipitate was filtered, washed 
with ethanol and crystallized from DMF/ethanol (4:1) into 
colourless crystals. 
Yield: 0.27g (87.7%), m.p.: 315-317 °C. IR = 3460, 3381 
(NH2), 3134 (NH), 3067 (CH arom.), 2987 (CH aliph.), 1707, 
1640 (C = O), 1572 & 1502 (C = C). 1H-NMR (DMSO-d6) 
δ 10.88 (s, 2H, 2NH, exchangeable), 7.52 (s, 4H, 2NH2, 
exchangeable), 7.36-7.19 (m, 10H, arom.), 5.06 (s, 4H, 
2NCH2), 3.18 (s, 2H, CH2). Anal. Calcd for C23H22N6O4 
(446.45), Calcd.: C, 61.87, H, 4.97, N, 18.82, Found: C, 
61.60, H, 5.34, N, 18.52.
1,9-Dibenzyl-5,10-dihydropyrido[2,3-d:6,5-d’]dipyrimi-
dine-2,4,6,8(1H,3H,7H,9H)-tetraones (5a,b)
Two methods were used to synthesize the target com-
pounds:
A- A mixture of 6-amino-1-benzyluracil (1a) (0.26 g, 1.2 
mmol), and excess of formalin (2 ml) or p-chloroben-
zaldehyde (1.2 mmol) in the presence of TEA (0.3 ml) 
in DMF (3.0 ml) was heated under reflux for 4-6 hours. 
The reaction mixture was evaporated under reduced 
pressure.  The residue was treated with ethanol (10 
ml), the formed precipitate was filtered, washed with 
ethanol and crystallized from DMF to afford 5a,b.
B- A mixture of 5,5’-methylene bis(6-amino-1-benzylu-
racil)  (4) (0.1 g, 0.22 mmol) and DMF (2 ml) in the 
presence of TEA (0.3 ml) was heated under reflux for 
1 hour.  The reaction mixture was evaporated under 
reduced pressure.  The residue was treated with 
ethanol (10 ml), the formed precipitate was filtered, 




Yield: A 37%, B 62%, m.p.= > 330 °C. IR= 3187 (NH), 3062 
(CH arom.), 2917, 2848 (CH aliph.), 1697-1650 (C = O), 
1595 (C = C), 735, 700 (monosubstituted phenyl). Anal. 
Calcd for C
23H19N5O4 (429.42), Calcd.: C, 64.33, H, 4.46, N, 
16.31, Found: C, 64.30, H, 4.34, N, 15.97.
5 - ( 4 - c h l o r o p h e n y l ) - 1 , 9 - d i b e n z y l - 5 , 1 0 -
dihydropyrido[2,3-d:6,5-d’]dipyrimidine-2,4,6,8 
(1H,3H,7H,9H)-tetraone (5b) 
Yield: A 58%, m.p.= > 330 °C. IR= 3134 (NH), 3054 (CH 
arom.), 2922, 2952 (CH aliph.), 1697-1616 (C = O), 1567 
(C = C), 844 (p-substituted phenyl), 724, 696 (monosubsti-
tuted phenyl). 1H-NMR (DMSO-d6) δ 10.96 (s, 2H, 2NH, ex-
changeable), 7.40 (bs, 1H, NH, exchangeable), 7.37-7.05 
(m, 14H, arom.), 5.43 (s, 1H, CH-5), 5.12 (s, 4H, 2NCH2). 
Anal. Calcd for C29H22ClN5O4 (539.96), Calcd.: C, 64.51, H, 
4.11, N, 12.97, Found: C, 64.75, H, 4.31, N, 13.21.
7-Aryl-1,3-dimethylpteridine-2,4(1H,3H)-diones (7a-d)
A mixture of 5,6-diamino-1,3-dimethyluracil hydrochloride 
(6) (0.29 g, 1.4 mmol) and the respective phenacyl bromide 
derivative (1.4 mmol) in ethanol (10 ml) in the presence of 
TEA (2.0 ml) was heated under reflux for 4-6 hours.  After 
cooling, the formed precipitate was filtered, washed with 
ethanol and crystallized from ethanol. 
1,3-Dimethyl-7-phenylpteridine-2,4(1H,3H)-dione (7a) 
Yield: 86%, m.p. lit.24= 308-309 °C, m.p.= 310-312 °C. IR= 
3065 (CH arom.), 2920, 2852 (CH aliph.), 1715, 1668 (2 C = 
O), 1547 (C = C), 750, 693 (monosubstituted benzene ring). 
1H-NMR (DMSO-d6) δ 9.18 (s, 1H, CH-6), 8.30- 8.27 (m, 2H, 
arom.), 7.61- 7.59 (m, 3H, arom.), 3.39 (s, 3H, NCH3), 3.33 
(s, 3H, NCH3). Anal. Calcd for C14H12N4O2 (268.27), Calcd.: 
C, 62.68, H, 4.51, N, 20.88, Found: C, 62.68, H, 4.10, N, 
20.70.
7- (4-Methoxypheny l ) -1 ,3-d imethy lpter id ine-
2,4(1H,3H)-dione (7b) 
Yield: 81%, m.p.= 288-290 °C. IR= 3062 (CH arom.), 2931, 
2849 (CH aliph), 1710, 1668 (2 C = O), 1538 (C = C), 841 
(p-substituted phenyl). MS: m/z 298 (M+, 99.57), 186 (100). 
Anal. Calcd for C15H14N4O3 (298.29), Calcd.: C, 60.40, H, 
4.73, N, 18.78, Found: C, 60.15, H, 4.04, N, 18.55.
1,3-Dimethyl-6,7-diphenylpteridine-2,4(1H,3H)-dione 
(7c)
Yield: 89%, m.p.= 227-229 °C. IR= 3060 (CH arom.), 
2959 (CH aliph), 1718, 1676 (2 C = O), 1549 (C = C), 749, 
697 (phenyl group). Anal. Calcd for C20H16N4O2 (344.36), 




Yield: 63%, m.p.= > 330 °C. IR= 3069 (CH arom.), 2962, 
2859 (CH aliph.), 1715, 1668 (2 C = O), 1545 (C = C), 1520, 
1343 (NO2), 852 (p-substituted phenyl). Anal. Calcd for 
C14H11N5O4 (313.26), Calcd.: C, 53.68, H, 3.54, N, 22.36, 
Found: C, 54.00, H, 3.95, N, 22.08.
Biological evaluation
Nucleic acids preparation
For extraction of genomic DNA, yeast cells were washed 
with cold phosphate borate sodium chloride (PBS) buffer 
and lysed in a buffer containing 50 mM Tris-HCl (pH 8.0), 
1 mM EDTA, 0.2% Triton X-100 for 20 min at 4 ºC.  After 
centrifugation at 14,000 rpm for 15 min, the supernatant 
was treated with proteinase K (0.5 mg/ml) and 1% SDS for 
1 h at 50 ºC.  DNA was extracted twice with buffered phe-
nol/chloroform and precipitated with 140 mM NaCl and 2 
volumes of ethanol at - 20 ºC overnight.  DNA precipitates 
were washed twice with 70% ethanol, air-dried and dis-
solved in TE buffer, and treated for 1 h at 37 ºC with RNase 
A according to reported method.25  Finally, DNA prepara-
tions were electrophoresed in 1% agarose gels.
Agarose gel preparation and visualization of DNA
1% Agarose gel was prepared by adding 1gm ultra aga-
rose to 100 ml Tris-Acetate-EDTA (TAE) buffer and heated 
in a microwave oven then cooled to ~60°C before pouring 
in gel tray. 
Examination of the gel was carried out using ultraviolet il-
luminated box.  Ethidium bromide (0.1 mg/ml) solution was 
used to stain the nucleic acid (DNA bands) in the gel as 
it intercalates between DNA bases and give florescence. 
The gel was photographed using polarized camera.
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Nucleic acid affinity, binding and fragmentation assay
The test compounds were dissolved in DMSO at 20 µg/µl 
concentrations, mixed with 2 µg/µl DNA and incubated at 
room temperature for 2 hrs.  The mixtures were mixed with 
the gel loading buffer and then electrophoresed in the aga-
rose gel (1% w/v) at 80 V for 1.5 hrs.  As positive control for 
affinity, binding and fragmentation, methotrexate (20 µg/µl) 
was mixed with DNA and as negative control DMSO was 
mixed with equal amount of DNA.  After running, agarose 




6-Amino-1-benzyl-[or 1-(2-chlorobenzyl)]uracil 1a,b were 
synthesized by the condensation of ethyl cyanoacetate 
with N-benzyluea26 or N-(2-chlorobenzyl)urea27 in sodium 
ethoxide or methoxide in good yields accoding to the re-
ported method. The synthetic strategy towards the desired 
pyridopyrimidines involves the addition of the nucleophilic 
enaminic carbon of aminouracil to the electrophilic carbon 
of an activated olefin.  Thus, refluxing of 6-aminouracil (1) 
with arylidenemalononitrile in dimethylformamide (DMF)28 
in the presence of triethylamine (TEA) as a base afforded 
pyridopyrimidines 2a-d in good yields. The formation of 
2a-d were carried out presumably via the formation of 
non-isolable acyclic Michael type adduct that undergo cy-
clization via the addition of nucleophilic nitrogen of amino 
group to the cyano- function and finally aromatization af-
fording the target pyridopyrimidines 2a-d. As illustrated 
in the synthesis of 2a-d, the reaction of aminouracil with 
ethyl arylideneacetoacetate was also investigated.  Thus, 
refluxing 6-amino-1-benzyl-[or 1-(2-chlorobenzyl)]uracil 
(1a or b) with ethyl arylidene-acetoacetate in DMF and in 































































































The reaction takes place presumably via the formation 
of nonisolable acyclic Michael type adduct  that under-
go subsequent elimination of COCH3 group
29 and finally 
cyclocondensation via the elimination of ethanol affording 
the final product 3a-d. An expected mechanism for this 
reaction may be as follows:
On the other hand, 5’-Methylene bis(6-amino-1-benzylura-
cil) (4) was obtained through the condensation of 6-amino-
1-benzyluracil (1a) with formalin in ethanol and acetic acid 
at room temperature. A simple method for the synthesis 
of pyridodipyrimidine 5a,b in  good yields was applied 
through the reaction of 6-amino-1-benzyluracil (1a) with 
formalin or 4-chlorobenzaldehyde in DMF in the presence 
of TEA as a base at the reflux temperature. A plausible 
reaction mechanism might be illustrated as follows: 
This mechanism was supported by the ease of cycliza-
tion of compound 4 to 5a when heated under reflux in the 
same medium (DMF/TEA) for one hour.  The project now 
directed towards the possible utility of diaminouracils for 
the synthesis of lumazines.  Thus, refluxing diaminouracil 
hydrochloride26, 30-32 6 and phenacyl bromides in the pres-
ence of triethylamine afforded lumazines 7a-d.  
Scheme 2
This may be presumably via the formation of nonisolable 
alkylated intermediate through SN
2 type reaction, followed 
by intramolecular cyclodehydration and final aromatization 
to lumazines.
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Biological evaluation 
The newly synthesized compounds were subjected to nu-
cleic acid binding assay using agarose gel electrophoresis 
method.
Nucleic acids binding assay:
Different synthetic drugs induced DNA damage was evalu-
ated by measuring the level of genomic DNA fragmenta-
tion and detecting DNA ladders on agrose gel electropho-
resis (Fig. 1). Compared to the vehicle control group (lane 
2 negative control and 3 positive control), there was no 
significant change in genomic DNA fragmentation in some 
treated groups. There were major differences in the re-
sponse of extracted DNA (from Lanes 4-13 in figure 1). It 
is possible that drugs exerted its effect solely by indirect 
mechanisms. This contrast may have been due to differ-
ent enzyme(s) being with differing susceptibilities to drugs.
Figure 1. Gel electrophoresis 1%w/v agrose of untreated 
and treated DNA. Lane M: Molecular weight marker (left 
side); Lane 1: Untreated nucleic acid; Lane 2: DMSO 
treated nucleic acid (negative control); Lane 3: Methotrex-
ate treated nucleic acid (positive control); Lanes 4-13: 
Compounds (2a-d, 3c, d, 7a-d) treated nucleic acid.
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